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Tarutani1, Tatsuo Iiyama2, Naoki Asao3, John DiGiovanni4 and Shigetoshi Sano1
Epidermal keratinocytes in psoriatic lesions are characterized by activated Stat3, and increased levels of
cytokines and growth factors that promote Stat3 activation have been found within psoriatic lesions. K5.Stat3C
transgenic mice, in which keratinocytes express a constitutively active Stat3, develop psoriasis-like skin lesions.
In this study, we examined whether STA-21, a small Stat3 inhibitor, could be useful in ameliorating the skin
lesions not only in the model mouse but also in human psoriasis. Treatment with STA-21 markedly inhibited the
cytokine-dependent nuclear translocation of Stat3 in normal human keratinocytes in vitro. Keratinocyte
proliferation was inhibited by STA-21 in a dose-dependent manner through downregulation of c-Myc and cyclin
D1, whereas involucrin, transglutaminase 1, and keratin 10 levels were upregulated. Topical application of
STA-21 abolished the generation of skin lesions in K5.Stat3C mice. Finally, we treated psoriasis patients with STA-
21-containing ointment in a nonrandomized study. Psoriatic lesions in six of the eight patients showed
improvement after topical STA-21 treatment for 2 weeks. Therefore, we conclude that targeting Stat3 may lead to
a therapy for psoriasis.
Journal of Investigative Dermatology (2011) 131, 108–117; doi:10.1038/jid.2010.255; published online 2 September 2010
INTRODUCTION
Our previous study elucidated the role of Stat3 signaling
in keratinocytes during the development of psoriatic
lesions (Sano et al., 2005a, 2008). K5.Stat3C transgenic
mice, in which Stat3 is constitutively active in keratino-
cytes, develop psoriasiform lesions after wounding stimuli
or topical treatment with the tumor promoter 12-O-tetra-
decanoylphorbol-13-acetate (TPA), which strongly suggests
that Stat3 activation is required for the development of
psoriasis.
Previous studies have shown that the IL-23/IL-17 pathway
is linked to the induction of a number of inflammatory
diseases, including multiple sclerosis, arthritis, inflammatory
bowel diseases, and psoriasis (Cua et al., 2003; Murphy et al.,
2003; Yen et al., 2006; Wilson et al., 2007). The most distinct
evidence for the role of IL-23/Th17 in psoriasis comes from
clinical studies. A clinical study showed that anti-IL-12/
IL-23p40 therapy is an effective treatment for psoriasis
(Krueger et al., 2007). Amelioration of psoriasis is associated
with reduced Th17 responses (Zaba et al., 2007; Haider et al.,
2008). IL-22, a cytokine produced from Th17, is elevated in
the blood of psoriasis patients (Wolk et al., 2006), and
triggering the IL-22R mediates the proliferation and migration
of keratinocytes via Stat3 activation (Boniface et al., 2005).
Furthermore, studies using gene-targeted mice and recon-
stituted human epidermis revealed that IL-22 mediates
acanthosis through the activation of Stat3 in keratinocytes,
which strongly suggests that IL-22, as an effector cytokine by
Th17, mediates the cross-talk between immunocytes and
keratinocytes in the pathogenesis of psoriasis (Sano et al.,
2005a; Sa et al., 2007; Zheng et al., 2007). In addition to
IL-22, other IL-20 subfamily cytokines, such as IL-19, IL-20,
IL-24, and IL-26, have been implicated in psoriasis and are
able to phosphorylate Stat3 in keratinocytes (Blumberg et al.,
2001; Romer et al., 2003; Boniface et al., 2005; Sa et al.,
2007; Tohyama et al., 2009; Wolk et al., 2009). Furthermore,
EGF family growth factors, including heparin-binding EGF-
like growth factor (HB-EGF), TGF-a, and amphiregulin, have
also been suggested to be important (Piepkorn, 1996;
Piepkorn et al., 1998). These EGF family growth factors are
produced by keratinocytes as autocrine/juxtacrine factors that
induce Stat3 activation (Sartor et al., 1997; Sano et al., 1999;
Tokumaru et al., 2005). Taken together, Stat3 has a major
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function in the signal transduction of psoriatic keratinocytes
in response to cytokine/growth factors. This notion supports
the idea that the use of Stat3 inhibitors could be an effective
therapy for psoriasis.
We showed previously that topical treatment of K5.Stat3C
transgenic mice with Stat3 decoy oligonucleotides inhibits
the de novo generation of psoriatic-like lesions and attenu-
ates the epidermal hyperplasia of preexisting lesions (Sano
et al., 2005a). However, as decoy oligonucleotides are too
large to be absorbed epicutaneously, we have searched for
small Stat3 inhibitors suitable for topical application. Song
et al. (2005) identified an antibiotic termed STA-21 (or
ochromycinone) as a Stat3 inhibitor, which blocks Stat3
dimerization and DNA binding, and in this study we tested
the efficacy of STA-21 in treating psoriatic lesions.
RESULTS
Stat3 activation in epidermal keratinocytes and increased
expression of Stat3-stimulatory ligands in psoriatic lesions
Immunohistochemistry with an anti-Stat3 antibody revealed
that epidermal keratinocytes in psoriatic lesions show an
intense Stat3 signal in nuclei (Figure 1a), indicating Stat3
activation as previously reported (Sano et al., 2005a).
However, Stat3 expression was obscure in the epidermis of
uninvolved skin from psoriasis patients and from normal
controls. It has been shown that cytokines (e.g., IL-20
subfamily cytokines) and growth factors (e.g., EGF subfamily
growth factors) that cause Stat3 activation are upregulated in
psoriasis (Cook et al., 1997; Blumberg et al., 2001; Boniface
et al., 2007; Nickoloff, 2007; Sa et al., 2007; Zheng et al.,
2007). We verified the transcriptional levels of mRNAs
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Figure 1. Activated Stat3 in psoriatic lesional skin and increased mRNA levels of IL-20 subfamily cytokines and HB-EGF. (a) Immunofluorescence staining with
an anti-Stat3 antibody showed activated Stat3 in epidermal keratinocytes of psoriatic lesions, whereas no Stat3 was detected in the uninvolved skin from
psoriasis patients or from normal control skin. Sections were counterstained with 46-diamidino-2-phenyl indole (DAPI). H&E, hematoxylin-eosin staining.
Bar¼250 mm. (b) Expression of IL-22, IL-20, IL-19, IL-4, and heparin-binding EGF-like growth factor (HB-EGF) mRNAs in lesional skin relative to uninvolved
skin from patients with psoriasis (n¼ 5). IL-20 subfamily cytokines and HB-EGF mRNAs were increased in the lesional skin, but IL-4 mRNA was not increased.
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encoding these cytokines in psoriatic lesions. Real-time RT-
PCR revealed that Stat3-stimulating ligands, including IL-22,
IL-20, IL-19, and HB-EGF, were upregulated in the involved
skin compared with the uninvolved skin, whereas IL-4 was
not increased (Figure 1b). These results suggest that these
molecules cause persistent Stat3 activation of keratinocytes
that could give rise to psoriatic changes.
STA-21 inhibits the nuclear translocation of Stat3 and the
proliferation of normal human keratinocytes in vitro
STA-21 (ochromycinone) is a known antibiotic and was
identified as a Stat3 inhibitor through virtual screening by
Song et al. (2005). STA-21 hinders Stat3 dimerization and its
nuclear translocation in human carcinoma cells, which
constitutively express activated Stat3 (Song et al., 2005).
We examined whether STA-21 inhibits Stat3 signaling in
normal human keratinocytes (NHK) as well. Stimulation of
NHK with EGF, IL-6, or IL-22 caused a rapid nuclear
translocation of Stat3 (Figure 2a, upper panels). However,
the addition of STA-21 to NHK inhibited the ligand-
dependent nuclear translocation of Stat3 (Figure 2a, lower
panels). This result indicates that STA-21 efficiently inhibits
Stat3 signaling in NHK as well as in cancer cell lines (Song
et al., 2005). The proliferation of NHK in culture stimulated
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Figure 2. STA-21 inhibits Stat3 signaling in NHK. (a) Pretreatment of normal human keratinocyte (NHK) in culture with 20mM STA-21 for 1 hour before
stimulation with EGF, IL-6, or IL-22 (100 ngml1 for 30minutes). Immunostaining with an anti-Stat3 antibody showed that EGF, IL-6, or IL-22 induced nuclear
translocation of Stat3, which was inhibited by STA-21. Bar¼ 50mm. (b) STA-21 inhibited NHK proliferation in a dose-dependent manner measured using the
MTS assay. Data are reported as mean relative cell numbers±SD. DMSO (0.2%) is the vehicle control. STA-21 concentrations at 0, 2.5, 5, 10, 20, and 40 are
indicated by lines in black, blue, green, purple, red, and orange, respectively. A representative result from four independent experiments is shown.
(c) Cytotoxicity assay of STA-21 in vitro. Lactate dehydrogenase (LDH) is measured using the supernatants of NHK cultured for 24 hours in the presence of
STA-21 at the indicated concentrations. NHK in DMSO (0.2%) alone and freeze–thaw control are set at 0 and 100% of LDH release, respectively. Data are
means±SD from triplicate cultures. (d) Downregulation of c-Myc and cyclin D1 mRNA in NHK by STA-21 (20 mM). Relative transcript levels measured by
real-time RT-PCR of the relative expression from NHK cultured in the presence of STA-21 for 24 hours (shaded bars) and for 48 hours (dotted bars) compared
with untreated cells (black bars) are shown. A representative result from three independent experiments is shown.
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with EGF was inhibited by STA-21 in a dose-dependent
manner (Figure 2b), whereas a significant increase in
cytotoxicity of STA-21 at the given concentrations was not
found (Figure 2c). Both cyclin D1 and c-Myc are Stat3
transcriptional targets and promote cell-cycle progression.
STA-21 downregulated cyclin D1 and c-Myc at the transcrip-
tional (Figure 2d) and protein levels (Figure 3c), which was
associated with an antiproliferative effect of STA-21.
STA-21 upregulates involucrin, transglutaminase 1, and
keratin 10 of NHK in vitro
Normal human keratinocytes cultured in the presence of
STA-21 underwent morphological changes and became large
and flattened. These changes resembled those found when
NHK are cultured in high calcium or with 1,25 (OH) vitamin
D (calcitoriol) (Figure 3a), known stimuli for in vitro
keratinocyte differentiation (Smith et al., 1986; Pillai et al.,
1990; Takahashi et al., 2003). This notion prompted us to
examine whether STA-21 also induced keratinocyte differ-
entiation markers in vitro as well. STA-21 elevated the levels
of mRNAs encoding involucrin, transglutaminase 1, and
keratin 10 but not keratin 14 (Figure 3b). Western blotting
analysis showed that STA-21 increased protein levels of
involucrin and transglutaminase 1, which is similar to the
effects of calcium and 1,25 (OH) vitamin D (calcitoriol)
(Figure 3c). A densitometric analysis of the western blots
revealed that STA-21 increased levels of involucrin and
transglutaminase 1 proteins up to 1.5- and 7.6-fold, respec-
tively, compared to the DMSO-treated controls. In contrast,
STA-21 decreased levels of c-Myc and cyclin D1 proteins to
0.5- and 0.4-fold, respectively, compared to the controls.
These changes correlated well with the changes in mRNA
levels (Figure 2d). Previous studies have shown that IL-22,
which is a Th17 cytokine and induces Stat3 activation of
keratinocytes, is critical in the development of psoriasis
through promotion of keratinocyte proliferation and down-
regulation of differentiation (Boniface et al., 2005; Wolk
et al., 2006; Sa et al., 2007; Nograles et al., 2008). Here, we
also verified the inhibitory effect of IL-22 on the expression of
K10 and involucrin in cultured NHK (Figure 3d). However,
simultaneous inclusion with STA-21 reversed the effect of IL-
22 and even increased their expression over the basal levels,
suggesting that IL-22-induced downregulation of the differ-
entiation markers might be attributed to Stat3 signaling.
In vivo inhibition of Stat3 nuclear translocation of epidermal
keratinocytes by topical treatment with STA-21
Our previous study showed that abrogation of Stat3 function
by a decoy oligonucleotide inhibits the onset and reverses the
bona fide psoriasiform lesions in K5.Stat3C mice, in which
keratinocytes express a constitutively active Stat3. It should
be noted that, compared with wild-type mice, K5.Stat3C
mice constitutively showed increased Stat3 nuclear localiza-
tion, which was further increased following tape stripping
(Figure 4a), which is a mechanical signal that induces
psoriatic lesions in these mice (Sano et al., 2005b). Strikingly,
topical STA-21 treatment at 1 hour before tape stripping
significantly reduced the amount of Stat3 nuclear localization
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Figure 3. STA-21 induces keratinocyte differentiation markers in vitro.
(a) Morphology of normal human keratinocyte (NHK) cultured 24hours in the
presence of STA-21 (10mM), high calcium (1.2mM), or calcitoriol (107M). Cells
became flattened and large when treated with STA-21, similar to cells treated
with calcium or calcitoriol. Bar¼ 250mm. (b) Increases in mRNA levels of
keratinocyte differentiation molecules, involucrin, transglutaminase 1 (TGase 1),
and keratin 10, but not keratin 14. NHKs were treated with STA-21 for 24hours
at concentrations of 0, 2.5, 5, 10, and 20mM (stepwise increments indicated
by triangles). Relative mRNA expression of treated versus untreated cells is
shown. A representative result from three independent experiments is shown.
(c) Western blotting of NHK cells treated with STA-21 (20mM), high calcium
(1.2mM), or calcitoriol (107M) for 48hours. STA-21 increased involucrin and
transglutaminase proteins up to 1.5- and 7.6-fold, respectively, compared to the
DMSO-treated control. In contrast, STA-21 decreased c-Myc and cyclin D1
proteins to 0.5- and 0.4-fold, respectively. (d) Downregulation of transcriptional
levels of K10 and involucrin by IL-22 and possible involvement of Stat3.
Stimulation of cultured NHKs with IL-22 (200ngml1) for 24hours reduced
the levels of involucrin (black bars) and K10 (shaded bars) mRNAs to
41 and 44% of the basal level, respectively. Simultaneous treatment with
STA-21 (20mM) overcomes the inhibitory effect of IL-22 on the expression
of both genes.
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in K5.Stat3C mice (Figure 4a and b). Because STA-21 is a
small molecule (MW¼306) with a high solubility in organic
solvents, such as acetone, this result suggested that STA-21
efficiently penetrated the epidermis, whereby it blocked the
Stat3 nuclear translocation of keratinocytes in vivo.
Topical treatment with STA-21 suppresses the development
of psoriasiform lesions on K5.Stat3C mice
The results of our study (Figure 4a) strongly suggested that
STA-21 would be suitable for epicutaneous application. First,
we examined whether STA-21 inhibited an early response to
topical TPA treatment on the ears of K5.Stat3C mice. There
was a marked epidermal hyperplasia following topical
treatment of K5.Stat3C mice with TPA compared with
wild-type mice (Sano et al., 2005a; Chan et al., 2008).
However, treatment with STA-21 almost completely inhibited
the TPA-induced epidermal hyperplasia in K.Stat3C mice
(Figure 5a and b). STA-21 attenuated not only the epidermal
hyperplasia but also the dermal cell infiltrates and the
capillary proliferation of the ear skin (Figure 5b). Bona fide
psoriasis-like lesions developed on the dorsal skin of
K5.Stat3C mice following treatments with TPA three times
every week for more than 1 month. Again, application of
STA-21 markedly inhibited the development of the psoriasi-
form lesions, and epidermal hyperplasia was not found in the
dorsal skin of mice treated with STA-21 (Figure 5c and d).
It should be noted that lesions at the tail base, which
developed spontaneously, still occurred in STA-21-treated
mice (Figure 5c, upper right panel), because we applied STA-
21 to the dorsal skin away from the tail (circle in Figure 5c).
Another transgenic mouse model, in which tamoxifen
induces Raf expression in keratinocytes, referred to as K14-
Raf:ER, showed reversible epidermal hyperplasia (Tarutani
et al., 2003). Following topical treatment with tamoxifen,
they developed acanthosis and dermal infiltrates, resembling
psoriasis (Tarutani et al., 2010), and the epidermis showed
activated Stat3 as well as upregulation of Raf/MAPK pathway
(Supplementary Figure S1a online). Interestingly, inhibition of
Stat3 signaling by topical treatment with STA-21 attenuated
epidermal hyperplasia in these mice, as shown in K5.Stat3C
mice (Supplementary Figure S1b, c, and d online). This result
suggested that Stat3 signaling, at least in part, contributed to
psoriasis-like phenotype in this mouse model, although it
remains unclear how Stat3 was activated in association with
activation of Raf/MAPK pathway. These results together
prompted us to carry out a clinical study with STA-21
ointment for psoriasis patients.
Effect of topical application of STA-21 ointment on psoriasis
lesions
Eight patients with psoriasis, who had not been treated with
systemic therapies in the previous 2 months, with UV therapy
in the previous 3 weeks, or with topical therapy in the
previous 2 weeks, were allocated to intervention in this study
for 2 weeks. To perform the study with intrapatient
comparison of the effect of STA-21 versus vehicle alone,
we selected two discrete macular lesions with almost the
same clinical severity on each patient: one being treated with
0.2% STA-21 in petrolatum, the other with petrolatum alone.
Generally, treatment with STA-21 ointment was well
tolerated in all study subjects. No patient was removed from
the study because of any apparent adverse effects, including
life-threatening toxicity, local irritation, and contact derma-
titis, during the trial.
We assessed the objective clinical scores of erythema,
induration, and scaling (Figure 6b). Score improvements by
STA-21 over vehicle alone were obtained in five patients
(patients 1–5), who showed 430% difference in the score
decline after 2 weeks treatment with STA-21 compared with
vehicle control. Representative photographs of responder
patients 1, 2 (Figure 6a), 3, and 5 (Supplementary Figure S1
online) are shown. Some improvement by petrolatum alone
was presumably due to the effect of the occlusive dressing
(patients 1, 2, 3, 4, 6, and 7), but such an effect was not
observed in patients 5 and 8, who did not apply occlusive
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Figure 4. A decrease in Stat3 nuclear localization of mouse epidermis
following topical treatment with STA-21. (a) Amount of nuclear-located
Stat3. The amount of nuclear-localized Stat3 in epidermis is constitutively
increased in K5.Stat3C mice, whereas that in wild-type mice is virtually
absent. Tape stripping immediately enhances the Stat3 translocation,
which is markedly inhibited by pretreatment with STA-21 (20 mg) at 1 hour
before tape stripping. Normal mice (n¼3), K5.Stat3C mice untreated (n¼ 3),
tape-stripped (TS) acetone control (n¼ 3), and STA-21 pretreated (n¼ 3).
Epidermal keratinocytes positive for nuclear Stat3 staining are counted in three
nonoverlapped fields per mouse. Data are mean number of cells positive
for nuclear Stat3 ±SD. **Po0.01, ***Po0.001. (b) Immunohistochemical
staining with anti-Stat3 of tape-stripped K5.Stat3C mouse skins pretreated
1hour earlier with acetone (top) and STA-21 (bottom). Lines,
epidermis–dermis border. Bar¼50 mm.
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dressing. However, any application of occlusive might not
greatly affect the outcome because the drug treatment was
performed under the same conditions as vehicle alone.
Although patient 6 showed no score improvement by STA-21
(Figure 6b), the lesion spreading was apparently inhibited by
STA-21 compared with vehicle control (Supplementary
Figure S2 online). Two of the eight patients (7 and 8 in
Supplementary Figure S1 online) did not show appreciable
response to the STA-21 ointment by the end of the 2-week
study, but vehicle alone did not outperform STA-21. Despite
the limited number of patients allocated and the short period
of the study, six of eight patients tested showed an
improvement (75%) when treated with STA-21 ointment
compared with control. Summary data for the mean clinical
score across all eight patients are shown in Figure 6c.
Compared with vehicle controls, STA-21-treated lesions
showed clinical improvement (P¼0.026 and 0.056 at days
7 and 14, respectively, by Mann–Whitney U-test). Taken
collectively, we expect that blocking Stat3 signaling by STA-
21 is a promising new modality for the treatment of psoriasis
and urge further randomized controlled research.
DISCUSSION
Our previous study showed that activated Stat3 in keratino-
cytes is found in psoriatic lesions and is required for the
generation of psoriasis-like lesions in K5.Stat3C mice (Sano
et al., 2005b). Psoriasis is associated with the overexpression
of cytokines and growth factors that can facilitate Stat3
activation. In this study, we examined whether a Stat3
inhibitor, STA-21, could improve psoriasis lesions. Topical
treatment with STA-21 not only inhibited the development of
psoriasiform lesions in K5.Stat3C mice but also ameliorated
psoriatic lesions in six of the eight psoriasis patients.
Th17 cells activated by IL-23 can produce IL-22, which is
responsible for epidermal hyperplasia through the activation
of Stat3 (Wolk et al., 2006; Zheng et al., 2007). It is
noteworthy that IL-20 subfamily cytokines, including IL-22,
IL-20, IL-19, IL-24, and IL-26, have been shown to be
upregulated in psoriasis lesions and they are able to activate
Stat3 (Blumberg et al., 2001; Romer et al., 2003; Boniface
et al., 2005; Sa et al., 2007; Tohyama et al., 2009; Wolk
et al., 2009). Furthermore, EGF family growth factors,
including HB-EGF, amphiregulin, and transforming growth
factor-a (TGF-a), which are secreted from keratinocytes and are
involved in psoriasis in an autocrine/juxtacrine manner, can
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Figure 5. Topical treatment with STA-21 inhibits the generation of
psorisiform lesions in K5.Stat3C mice. (a) STA-21 inhibited an early 12-O-
tetradecanoylphorbol-13-acetate (TPA) response of the ear skin in K5.Stat3C
mice. Ear skins of transgenic mice topically treated at days 1 and 3 with
0.64 nmol TPA or acetone alone were sampled at day 4. Although TPA
induced epidermal hyperplasia (black bars), treatment with STA-21 (10 mg) for
3 consecutive days significantly reduced the TPA-induced epidermal
thickness (red bars). Results are shown as mean thickness (mm) ±SD,
***Po0.001, n¼ 6 and 5 (untreated and STA-21 treated, respectively).
(b) Representative histological features of STA-21-treated ear skin.
TPA-induced histological changes in the ear skin of K5.Stat3C mice
(left panel) include epidermal hyperplasia, hyperkeratosis, dermal infiltrates
(arrows), capillary proliferation, and dilation (arrowheads). STA-21 treatment
markedly diminished those changes (right panel). H&E, hematoxylin-eosin
staining. Bar¼ 100 mm. (c) STA-21 inhibited the development of bona fide
psoriasiform lesions on the dorsal skin. Topical TPA treatment (3.4 nmol) three
times a week induced psoriasiform lesions on the back (upper right), with
psoriasis-like histological changes (lower right). Application of STA-21 (20 mg)
three times a week to the TPA-treated area (depicted by circles) completely
inhibited the generation of psoriasiform lesions macro- and microscopically
(right panels). Bar¼ 300mm. (d) Assessment of epidermal thickness. Black bar,
vehicle controls (n¼ 6); red bar, STA-21 treated (n¼5). Data are reported as
mean thickness (mm) ±SD, ***Po0.0001.
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also induce Stat3 activation (Sartor et al., 1997; Sano et al.,
1999; Tokumaru et al., 2005). Furthermore, IL-6 and another
family member (Oncostatin M) are also upregulated in psoriasis
lesions, and they can also cause Stat3-mediated keratinocyte
alterations (Boniface et al., 2007). In this study, we confirmed
that psoriasis lesions generally express higher levels of IL-20
Vehicle
STA-21
Vehicle
STA-21
0 7 11
0 7 12
Patient 1
Patient 2
Patient 1 2 3 4 5
8
6
4
2
0
8
6
4
2
0
0 1 2
0 1 2 0 1 2 0 1 2 0 1 2
0 1 2 0 1 2 0 1 2 0 1 2 (week)
(week)(week)
6 7 8
100
80
20
60
40
M
ea
n 
cl
in
ic
al
 s
co
re
 (%
)
*
(day)
(day)
Figure 6. Efficacy of topical treatment with STA-21 on psoriatic lesions. (a) Psoriatic lesions of two patients during the course (patient 1, a 56-year-old man;
patient 2, a 83-year-old man). Improvement of psoriasis lesions following application of STA-21 on the indicated days compared with vehicle controls
(Vaseline). (b) Sum of clinical scores of baseline, 1 week, and 2 weeks of lesions from all eight patients allocated in this study. Black line, Vaseline control; red
line, STA-21 treated. Five patients (patients 1–5), who showed430% difference in the score decline after 2 weeks treatment with STA-21 compared with vehicle
control, are considered to be responders based on the scores. D% Score decline in patients 1–8: 50, 38, 31, 35, 63, 0, 0, and 14, respectively. (c) Summary data
for the mean of clinical score across all eight patients. Mean±SD percent of the initial score is shown. Compared with vehicle controls (black line), STA-21-
treated lesions (red line) showed clinical improvement. *P¼0.026 (o0.05) and 0.056 at days 7 and 14, respectively.
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subfamily cytokines and HB-EGF than are found in uninvolved
skin. Taken collectively, it seems plausible that the cytokine/
growth factor profile associated with psoriasis converges on
Stat3 signaling in epidermal keratinocytes.
Psoriasis is characterized by keratinocyte hyperprolifera-
tion and altered differentiation. The in vitro effect of STA-21
on NHK was similar to that of vitamin D3, that is, inhibition
of keratinocyte proliferation and upregulation of involucrin
and transglutaminase 1 (Smith et al., 1986; Takahashi et al.,
2003). It has been demonstrated that IL-22 stimulates Stat3
activation of keratinocytes and induces proliferation but
downregulates differentiation (Boniface et al., 2005; Wolk
et al., 2006; Sa et al., 2007; Nograles et al., 2008), suggesting
the involvement of activated Stat3 in psoriasis. We showed
the inhibitory effect of IL-22 on the expression of transglu-
taminase 1 and K10, which was reversed for both by
simultaneous inclusion with STA-21. Therefore, it is reason-
able that topical application of the Stat3 inhibitor STA-21
would prevent the development of psoriasiform lesions in
K5.Stat3C mice and would improve the clinical severity of
lesions in psoriasis patients. However, we could not exclude
the possibility that STA-21 inhibited other molecules than
Stat3, although STA-21 was initially considered to be Stat3
specific (Song et al., 2005). Furthermore, it remains to be
determined whether the Stat3 signaling directly or indirectly
affects epidermal differentiation in psoriasis. Future study will
clarify the overall role of Stat3 in the pathogenesis of psoriasis.
An alternative, but not mutually exclusive, possibility is
that STA-21 could inhibit Th17 differentiation, as Stat3
activation is an indispensable event for the differentiation of
naive CD4 T cells to Th17 (Chen et al., 2007; Mathur et al.,
2007; Yang et al., 2007). Patients with hyperimmunoglobulin
E syndrome, or Job syndrome, show an impairment of Th17
development, because their T cells harbor dominant-negative
mutations in Stat3 (de Beaucoudrey et al., 2008; Ma et al.,
2008). Further examination to determine whether STA-21
affects Th17 differentiation/maturation in psoriasis lesions
will be required to resolve this possibility.
Eight patients with plaque-type psoriasis were allocated in
this study, and six of them (75%) showed a favorable
response to STA-21 compared with the vehicle control.
Assessment using clinical severity scores revealed that
treatment with STA-21 improved the lesions in five of the
eight patients. One patient showed a response in which
STA-21 apparently suppressed the enlargement of the lesion.
This study was a nonrandomized trial with a limited number
of patients and was unmasked because the STA-21 ointment
was of a different color. A randomized control trial will be
required in the future. Further studies will be necessary, for
example, dose optimization, comparison to topical vitamin
D3 or steroids, and histological assessment of treated skin. In
conclusion, targeting Stat3 might result in an effective
alternative therapy for psoriasis.
MATERIALS AND METHODS
Please see details of the following in the Supplementary Data online.
Cell culture and reagents
Immunostaining with anti-Stat3 antibody
Cell proliferation assay (MTS assay), cytotoxic assay (LDH release
assay)
RNA isolation and real-time RT-PCR
Western blotting
Topical treatment with STA-21 in skin lesions of K14-Raf:ER
transgenic mice
Determination of STA-21 dose for in vivo treatment
K5.Stat3C transgenic mice, early TPA responses in the ear,
induction of psoriasiform lesions, and topical application
of STA-21
All experimental procedures performed on mice were approved by
the institutional animal care and use committee of the Kochi Medical
School. K5.Stat3C mice were generated as previously reported (Sano
et al., 2005b). Briefly, Stat3C cDNA (a gift from Dr Bromberg) was
ligated into the pBK5 construct, followed by digestion with EcoRI.
The construct was then used to generate transgenic founder mice on
an FVB background. Transgenic mice were identified by PCR of
genomic DNA with primers specific for the gene encoding rabbit
b-globin; 50-TTCAGGATGTTGTTTAGAATGG-30 and 50-CAATAAG
AATATTTCCACGCCA-30. To examine the in vivo effect of STA-21,
we topically treated with 20 mg STA-21 in acetone (100ml) or
acetone alone on the K5.Stat3 mouse back skin after shaving the
hair. After 1 hour, 15 strokes of tape stripping were carried out at
the treated sites. After another hour, skin specimens were taken
for immunohistochemical examination by Stat3 staining. The early
TPA response was conducted by topical treatment with 0.68 nmol
TPA (Sigma, St Louis, MI) in 20 ml acetone on the right ear of each
mouse, with 20 ml acetone on the left ear as the vehicle control
on days 1 and 3. STA-21 (10 mg) or vehicle alone (acetone) was
topically applied to the ears for 3 consecutive days, and the ear skins
were sampled on day 4. The generation of bona fide psoriasiform
lesions was as described previously (Sano et al., 2005b). Briefly,
K5.Stat3C mice were topically treated with 3.4 nmol TPA in 100 ml
acetone three times a week on the dorsal skin after shaving.
Application of either 20 mg STA-21 or vehicle alone (acetone) to
the TPA-treated sites was carried out three times a week. After
7–8 weeks, mice were killed under anesthesia with sodium pento-
barbital, and the dorsal skins were excised. All mouse experiments
were performed with strict adherence to institutional guidelines for
minimizing distress.
Patients and clinical study design
The clinical assessment of patients with plaque-type psoriasis was
performed by open, nonrandomized, intrapatient comparison of
STA-21 with vehicle alone with 2-week follow-up. The clinical study
was conducted at the Department of Dermatology, Kochi Medical
School Hospital in Nankoku, Kochi, Japan, in accordance with the
Declaration of Helsinki Principles, and it has been registered at
ClinicalTrials.gov (registration no. NCT01047943). All patients
provided written informed consent before inclusion in the study,
and the study protocol was approved by the institutional ethical
review board of the Kochi Medical School, Kochi University. The
protocols are described in detail in Supplementary Data online.
Outcome measures
Clinical assessment of psoriatic lesion severity was performed at the
baseline and at weeks 1 and 2 (end of treatment). Two dermatologists
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assessed efficacy using the scores of erythema, induration, and
scaling and the sum of these scores of target plaques (modified
Psoriasis Area Severity Index). Erythema, induration, and scaling
were scored on a scale of 0–4 (0 indicating none; 1, mild; 2,
moderate; 3, severe; 4, very severe). Because the STA-21 ointment
was orange, the assessors were aware of which lesions were treated
with STA-21. Clinical photographs were taken at each visit.
Toxic effects and adverse reactions associated with administra-
tion of STA-21 were noted at daily physical examinations,
termination of the treatment, and follow-up period. Any signs of
local irritation at the application site, abnormal vital signs, clinically
significant abnormal laboratory findings, or other symptoms
occurring were recorded for consideration as toxic effects or adverse
reactions and evaluated following version 3.0 of the National Cancer
Institute’s Common Terminology Criteria for Adverse Events.
Statistical analysis
The statistical significance of differences between means was
determined by Mann–Whitney U-test. Po0.05 was considered to
be statistically significant.
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